Sone-ve Stomach Cancer Drug Extends Survival in Trial
Published On 27 Oct, 2026
9 News HD: A new stomach cancer drug called Sone-ve has shown promising results in a late-stage clinical trial, helping patients with advanced cancer live longer than those who received standard chemotherapy.
The drug is being developed by AstraZeneca for people with advanced stomach and related cancers whose disease has returned or continued to grow after earlier treatments.
In the trial, patients who had already received at least two treatments lived for a median of 10 months with Sone-ve. Those who received chemotherapy chosen by their doctors lived for a median of five months. The results suggest that the drug could offer a new treatment option for patients with limited choices.
The findings were presented at a major cancer research meeting in Madrid, Spain, on October 25, 2026. The study included 532 patients and compared Sone-ve with chemotherapy.
Sone-ve is designed to carry cancer-fighting medicine to cells with a specific protein called CLDN18.2. This protein is found in some stomach cancer cells, allowing the treatment to target those cells.
However, the results were not positive across every main goal of the study. The drug did not meet the required statistical target for delaying cancer progression, meaning further research is still needed to understand its full benefits.
Researchers are also studying Sone-ve in other trials to learn whether it could help patients at earlier stages of treatment.
Although the results offer hope, Sone-ve remains an experimental medicine, and the findings do not mean it is already approved for general use. More research and regulatory review will be needed before its availability can be confirmed.
